Theravance Biopharma (TBPH) Short term Debt (2019 - 2022)

Theravance Biopharma (TBPH) has 4 years of Short term Debt data on file, last reported at $9.0 million in Q1 2022.

• On a quarterly basis, Short term Debt fell 22.7% year-over-year to $9.0 million in Q1 2022; TTM through Mar 2022 was $9.0 million, a 22.7% decrease from a year earlier, with the FY2021 full-year figure at $16.9 million, down 12.38% from the prior year.
• Short term Debt for Q1 2022 stood at $9.0 million, down from $16.9 million in the prior quarter.
• Over the last five years, Short term Debt for TBPH reached as high as $19.3 million in Q4 2020 and fell as low as $6.9 million in Q2 2021.
• Historically, Short term Debt has averaged $11.6 million across 4 years, with a median of $10.8 million in 2019.
• Across the five-year window, Short term Debt soared 96.26% in 2020 and slipped 22.7% in 2022, its largest moves.
• Year by year, Short term Debt stood at $9.9 million in 2019, then surged by 96.26% to $19.3 million in 2020, then dropped by 12.38% to $16.9 million in 2021, then tumbled by 46.8% to $9.0 million in 2022.
• Per Business Quant data, the three most recent Short term Debt figures were $9.0 million in Q1 2022, $16.9 million in Q4 2021, and $12.5 million in Q3 2021.